サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1438227

ピーナッツアレルギー治療市場の2030年までの予測：治療タイプ別、投与経路別、エンドユーザー別、地域別の世界分析

Peanut Allergy Treatment Market Forecasts to 2030 - Global Analysis By Treatment Type (Epinephrine, Antihistamines & Corticosteroids, Immunotherapy & Other Treatment Types), By Route Of Administration (Oral & Injectable), End User & By Geography

出版日
ページ情報
英文 200+ Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
ピーナッツアレルギー治療市場の2030年までの予測：治療タイプ別、投与経路別、エンドユーザー別、地域別の世界分析
出版日: 2024年02月02日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Stratistics MRCによると、ピーナッツアレルギー治療の世界市場は2023年に5億1,610万米ドルを占め、2030年には11億6,980万米ドルに達すると予測され、予測期間中のCAGRは12.4％です。

ピーナッツアレルギー治療には、ピーナッツの摂取によって引き起こされるアレルギー反応を管理・緩和するための様々な戦略が含まれます。アプローチには、アレルゲンの回避、エピネフリンによる緊急介入、免疫系の脱感作を目的としたアレルゲン免疫療法などがあります。これらの治療法は、患者の安全性を高め、アレルギー反応を最小限に抑え、ピーナッツ・アレルギーを持つ人の全体的な生活の質を向上させることを目的としています。

ITCの貿易マップによると、2021年にはアルゼンチンが63万4,080トンのピーナッツを輸出し、次いでインドが56万3,268トンで2位でした。

ピーナッツアレルギーの有病率の増加

ピーナッツアレルギーと診断される人が世界的に増加する中、効果的な治療法の必要性が高まっています。この動向は、アレルゲン免疫療法、緊急介入、予防策を含む革新的な治療法に向けた研究開発の推進力となっています。さらに、ピーナッツアレルギーに関連するリスクを管理・軽減するための高度で利用しやすい治療法に対する需要に製薬会社やヘルスケアプロバイダーが対応しているため、患者層の拡大が市場の成長を促進しています。

高額な治療費

アレルゲン免疫療法、緊急介入、継続的な医学的管理に関連する費用は、患者やヘルスケアシステムの経済的負担の一因となっています。特定の治療に対する保険適用が限られていることが、費用の障壁をさらに悪化させています。このような経済的な敷居の高さが、治療を求めたり継続したりすることを躊躇させ、患者のアドヒアランスや治療成績全体に影響を及ぼすこともあります。

認知度と診断率の上昇

ピーナッツアレルギーに対するヘルスケア専門家や一般市民の認識が高まることで、早期発見・早期診断が可能になります。認知度が高まるにつれて、より多くの患者が医療機関を受診するようになり、治療の選択肢となる患者数が増加します。この動向は、タイムリーな介入を可能にすることで患者の転帰を改善するだけでなく、効果的なピーナッツアレルギー治療に対する需要も促進します。公開会社とヘルスケアプロバイダーは、革新的な治療法を開発し、教育イニシアチブを促進し、医療界と一般市民の双方におけるピーナッツアレルギーのより包括的な理解に貢献することで、この機会を活用することができます。

専門医や治療センターへのアクセス制限

専門医や治療センターへのアクセスが限られていることは、ピーナッツアレルギー治療市場にとって大きな脅威です。ピーナッツ・アレルギーに直面している患者は、専門的なヘルスケア・プロフェッショナルや指定された治療施設にアクセスする際に課題に遭遇する可能性があります。この制限は、タイムリーな診断、個別化された治療計画、アレルゲン免疫療法の実施を妨げる可能性があります。訓練を受けた専門医の不足は、患者ケアにおけるギャップの一因となり、介入の効果に影響を与える可能性があります。

COVID-19の影響

COVID-19の大流行は、アレルギー診断や治療を含むヘルスケア・サービスの混乱を引き起こし、ピーナッツ・アレルギー治療市場に影響を与えています。閉鎖、制限、ヘルスケアの優先順位のシフトにより、患者のケア、診断、治療開始が遅れました。さらに、パンデミックは臨床試験や研究活動にも影響を及ぼし、ピーナッツアレルギー治療の全体像に影響を与えました。状況が安定するにつれ、患者の安全性と革新的な治療アプローチが重視されるようになり、市場は徐々に回復しつつあります。

予測期間中、免疫療法分野が最大となる見込み

予測期間中、ピーナッツアレルギー治療市場では免疫療法分野が最大となる見込みです。この優位性は、ピーナッツに対する免疫系の減感作を目的とした皮下および舌下アプローチを含むアレルゲン免疫療法の採用が増加していることに起因しています。ピーナッツ・アレルギーの根本原因への対処とアレルギー反応の軽減に重点を置く免疫療法は、好ましい治療オプションとして台頭し、同分野の大幅な市場シェア拡大に寄与しています。

予測期間中にCAGRが最も高くなると予測されるのは注射剤セグメントです。

予測期間中、ピーナッツアレルギー治療市場は注射剤分野で有利な成長が見込まれます。この成長の原動力となっているのは、注射剤による治療、特に重度のアレルギー反応の緊急管理におけるエピネフリン自動注射器の使用に対する嗜好の高まりです。アレルギー緊急時の迅速かつ効率的な介入への注目が高まる中、注射剤セグメントは患者や介護者に便利で効果的なソリューションを提供し、大幅な成長を遂げる見通しです。

最大のシェアを占める地域

北米は、高度なヘルスケア・インフラ、ピーナッツ・アレルギーに対する意識の高まり、積極的な規制環境により、ピーナッツ・アレルギー治療市場を独占する見通しです。同地域は、免疫療法を含む革新的な治療法に注力しており、ピーナッツアレルギーの有病率が高いことも、市場をリードする要因となっています。さらに、医療機関と研究機関の連携がピーナッツアレルギー治療の進歩を促進し、北米を開発および市場開拓の主な拠点として位置づけています。

CAGRが最も高い地域

欧州地域では、ピーナッツアレルギーの有病率の増加、ヘルスケア研究の重視、治療オプションの進歩により、ピーナッツアレルギー治療市場の急成長が予測されます。ヘルスケア専門家および患者における認知度の向上は、支持的な規制の枠組みと相まって、革新的なピーナッツアレルギー治療の採用を後押ししています。研究開発の強化に伴い、欧州はピーナッツアレルギー治療の進歩に大きく貢献し、予測期間における市場の大幅な成長を牽引しています。

無料カスタマイズサービス

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

  • 企業プロファイル
    • 追加市場プレイヤーの包括的プロファイリング（3社まで）
    • 主要企業のSWOT分析（3社まで）
  • 地域セグメンテーション
    • 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
  • 競合ベンチマーキング
    • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

  • 概要
  • ステークホルダー
  • 調査範囲
  • 調査手法
    • データマイニング
    • データ分析
    • データ検証
    • 調査アプローチ
  • 調査ソース
    • 1次調査ソース
    • 2次調査ソース
    • 前提条件

第3章 市場動向分析

  • 促進要因
  • 抑制要因
  • 機会
  • 脅威
  • エンドユーザー分析
  • COVID-19の影響

第4章 ポーターのファイブフォース分析

  • 供給企業の交渉力
  • 買い手の交渉力
  • 代替品の脅威
  • 新規参入業者の脅威
  • 競合企業間の敵対関係

第5章 世界のピーナッツアレルギー治療市場：治療タイプ別

  • エピネフリン
  • 抗ヒスタミン薬とコルチコステロイド
  • 免疫療法
  • その他の治療タイプ

第6章 世界のピーナッツアレルギー治療市場：投与経路別

  • オーラル
  • 注射可能

第7章 世界のピーナッツアレルギー治療市場：エンドユーザー別

  • 病院
  • クリニック
  • 外来手術センター
  • ホームケア設定

第8章 世界のピーナッツアレルギー治療市場：地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • イタリア
    • フランス
    • スペイン
    • その他欧州
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • オーストラリア
    • ニュージーランド
    • 韓国
    • その他アジア太平洋地域
  • 南米
    • アルゼンチン
    • ブラジル
    • チリ
    • その他南米
  • 中東とアフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • カタール
    • 南アフリカ
    • その他中東とアフリカ

第9章 主な発展

  • 契約、パートナーシップ、コラボレーション、合弁事業
  • 買収と合併
  • 新製品の発売
  • 事業拡大
  • その他の主要戦略

第10章 企業プロファイル

  • Aimmune Therapeutics
  • ALK-Abello A/S
  • Alladapt Immunotherapeutics, Inc
  • AnaptysBio, Inc.
  • DBV Technologies SA
  • GlaxoSmithKline plc
  • HAL Allergy Group
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG
  • Pfizer Inc.
  • Prota Therapeutics
  • Regeneron Pharmaceuticals
  • Sanofi
  • Stallergenes Greer
図表

List of Tables

  • Table 1 Global Peanut Allergy Treatment Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Peanut Allergy Treatment Market Outlook, By Treatment Type (2021-2030) ($MN)
  • Table 3 Global Peanut Allergy Treatment Market Outlook, By Epinephrine (2021-2030) ($MN)
  • Table 4 Global Peanut Allergy Treatment Market Outlook, By Antihistamines and Corticosteroids (2021-2030) ($MN)
  • Table 5 Global Peanut Allergy Treatment Market Outlook, By Immunotherapy (2021-2030) ($MN)
  • Table 6 Global Peanut Allergy Treatment Market Outlook, By Other Treatment Types (2021-2030) ($MN)
  • Table 7 Global Peanut Allergy Treatment Market Outlook, By Route Of Administration (2021-2030) ($MN)
  • Table 8 Global Peanut Allergy Treatment Market Outlook, By Oral (2021-2030) ($MN)
  • Table 9 Global Peanut Allergy Treatment Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 10 Global Peanut Allergy Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 11 Global Peanut Allergy Treatment Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 12 Global Peanut Allergy Treatment Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 13 Global Peanut Allergy Treatment Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 14 Global Peanut Allergy Treatment Market Outlook, By Homecare Settings (2021-2030) ($MN)
  • Table 15 North America Peanut Allergy Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 16 North America Peanut Allergy Treatment Market Outlook, By Treatment Type (2021-2030) ($MN)
  • Table 17 North America Peanut Allergy Treatment Market Outlook, By Epinephrine (2021-2030) ($MN)
  • Table 18 North America Peanut Allergy Treatment Market Outlook, By Antihistamines and Corticosteroids (2021-2030) ($MN)
  • Table 19 North America Peanut Allergy Treatment Market Outlook, By Immunotherapy (2021-2030) ($MN)
  • Table 20 North America Peanut Allergy Treatment Market Outlook, By Other Treatment Types (2021-2030) ($MN)
  • Table 21 North America Peanut Allergy Treatment Market Outlook, By Route Of Administration (2021-2030) ($MN)
  • Table 22 North America Peanut Allergy Treatment Market Outlook, By Oral (2021-2030) ($MN)
  • Table 23 North America Peanut Allergy Treatment Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 24 North America Peanut Allergy Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 25 North America Peanut Allergy Treatment Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 26 North America Peanut Allergy Treatment Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 27 North America Peanut Allergy Treatment Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 28 North America Peanut Allergy Treatment Market Outlook, By Homecare Settings (2021-2030) ($MN)
  • Table 29 Europe Peanut Allergy Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 30 Europe Peanut Allergy Treatment Market Outlook, By Treatment Type (2021-2030) ($MN)
  • Table 31 Europe Peanut Allergy Treatment Market Outlook, By Epinephrine (2021-2030) ($MN)
  • Table 32 Europe Peanut Allergy Treatment Market Outlook, By Antihistamines and Corticosteroids (2021-2030) ($MN)
  • Table 33 Europe Peanut Allergy Treatment Market Outlook, By Immunotherapy (2021-2030) ($MN)
  • Table 34 Europe Peanut Allergy Treatment Market Outlook, By Other Treatment Types (2021-2030) ($MN)
  • Table 35 Europe Peanut Allergy Treatment Market Outlook, By Route Of Administration (2021-2030) ($MN)
  • Table 36 Europe Peanut Allergy Treatment Market Outlook, By Oral (2021-2030) ($MN)
  • Table 37 Europe Peanut Allergy Treatment Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 38 Europe Peanut Allergy Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 39 Europe Peanut Allergy Treatment Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 40 Europe Peanut Allergy Treatment Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 41 Europe Peanut Allergy Treatment Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 42 Europe Peanut Allergy Treatment Market Outlook, By Homecare Settings (2021-2030) ($MN)
  • Table 43 Asia Pacific Peanut Allergy Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 44 Asia Pacific Peanut Allergy Treatment Market Outlook, By Treatment Type (2021-2030) ($MN)
  • Table 45 Asia Pacific Peanut Allergy Treatment Market Outlook, By Epinephrine (2021-2030) ($MN)
  • Table 46 Asia Pacific Peanut Allergy Treatment Market Outlook, By Antihistamines and Corticosteroids (2021-2030) ($MN)
  • Table 47 Asia Pacific Peanut Allergy Treatment Market Outlook, By Immunotherapy (2021-2030) ($MN)
  • Table 48 Asia Pacific Peanut Allergy Treatment Market Outlook, By Other Treatment Types (2021-2030) ($MN)
  • Table 49 Asia Pacific Peanut Allergy Treatment Market Outlook, By Route Of Administration (2021-2030) ($MN)
  • Table 50 Asia Pacific Peanut Allergy Treatment Market Outlook, By Oral (2021-2030) ($MN)
  • Table 51 Asia Pacific Peanut Allergy Treatment Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 52 Asia Pacific Peanut Allergy Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 53 Asia Pacific Peanut Allergy Treatment Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 54 Asia Pacific Peanut Allergy Treatment Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 55 Asia Pacific Peanut Allergy Treatment Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 56 Asia Pacific Peanut Allergy Treatment Market Outlook, By Homecare Settings (2021-2030) ($MN)
  • Table 57 South America Peanut Allergy Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 58 South America Peanut Allergy Treatment Market Outlook, By Treatment Type (2021-2030) ($MN)
  • Table 59 South America Peanut Allergy Treatment Market Outlook, By Epinephrine (2021-2030) ($MN)
  • Table 60 South America Peanut Allergy Treatment Market Outlook, By Antihistamines and Corticosteroids (2021-2030) ($MN)
  • Table 61 South America Peanut Allergy Treatment Market Outlook, By Immunotherapy (2021-2030) ($MN)
  • Table 62 South America Peanut Allergy Treatment Market Outlook, By Other Treatment Types (2021-2030) ($MN)
  • Table 63 South America Peanut Allergy Treatment Market Outlook, By Route Of Administration (2021-2030) ($MN)
  • Table 64 South America Peanut Allergy Treatment Market Outlook, By Oral (2021-2030) ($MN)
  • Table 65 South America Peanut Allergy Treatment Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 66 South America Peanut Allergy Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 67 South America Peanut Allergy Treatment Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 68 South America Peanut Allergy Treatment Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 69 South America Peanut Allergy Treatment Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 70 South America Peanut Allergy Treatment Market Outlook, By Homecare Settings (2021-2030) ($MN)
  • Table 71 Middle East & Africa Peanut Allergy Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 72 Middle East & Africa Peanut Allergy Treatment Market Outlook, By Treatment Type (2021-2030) ($MN)
  • Table 73 Middle East & Africa Peanut Allergy Treatment Market Outlook, By Epinephrine (2021-2030) ($MN)
  • Table 74 Middle East & Africa Peanut Allergy Treatment Market Outlook, By Antihistamines and Corticosteroids (2021-2030) ($MN)
  • Table 75 Middle East & Africa Peanut Allergy Treatment Market Outlook, By Immunotherapy (2021-2030) ($MN)
  • Table 76 Middle East & Africa Peanut Allergy Treatment Market Outlook, By Other Treatment Types (2021-2030) ($MN)
  • Table 77 Middle East & Africa Peanut Allergy Treatment Market Outlook, By Route Of Administration (2021-2030) ($MN)
  • Table 78 Middle East & Africa Peanut Allergy Treatment Market Outlook, By Oral (2021-2030) ($MN)
  • Table 79 Middle East & Africa Peanut Allergy Treatment Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 80 Middle East & Africa Peanut Allergy Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 81 Middle East & Africa Peanut Allergy Treatment Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 82 Middle East & Africa Peanut Allergy Treatment Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 83 Middle East & Africa Peanut Allergy Treatment Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 84 Middle East & Africa Peanut Allergy Treatment Market Outlook, By Homecare Settings (2021-2030) ($MN)
目次
Product Code: SMRC25196

According to Stratistics MRC, the Global Peanut Allergy Treatment Market is accounted for $516.1 million in 2023 and is expected to reach $1169.8 million by 2030 growing at a CAGR of 12.4% during the forecast period. Peanut allergy treatment involves various strategies to manage and alleviate allergic reactions triggered by the consumption of peanuts. Approaches include allergen avoidance, emergency interventions with epinephrine, and allergen immunotherapy, aimed at desensitizing the immune system. These treatments aim to enhance patient safety, minimize allergic responses, and improve the overall quality of life for individuals with peanut allergies.

According to the ITC trade map, in 2021, Argentina exported 634,080 metric ton of peanuts, followed by India with 563,268 metric ton in second place.

Market Dynamics:

Driver:

Increasing prevalence of peanut allergy

With a rising number of individuals diagnosed with peanut allergies globally, there is a growing need for effective treatment options. This trend propels research and development efforts towards innovative therapies, including allergen immunotherapy, emergency interventions, and preventive measures. Moreover, the expanding patient pool fosters market growth as pharmaceutical companies and healthcare providers address the demand for advanced and accessible treatments to manage and mitigate the risks associated with peanut allergies.

Restraint:

High cost of treatment

Expenses associated with allergen immunotherapy, emergency interventions, and ongoing medical management contribute to the financial burden on patients and healthcare systems. Limited insurance coverage for certain treatments further exacerbates the cost barrier. This high financial threshold may deter some individuals from seeking or continuing treatment, impacting overall patient adherence and outcomes.

Opportunity:

Rising awareness and diagnosis rates

Increased awareness among healthcare professionals and the general public about peanut allergies leads to early detection and diagnosis. As awareness grows, more individuals seek medical attention, creating a larger patient pool for treatment options. This trend not only improves patient outcomes by enabling timely interventions but also drives the demand for effective peanut allergy treatments. Pharmaceutical companies and healthcare providers can capitalize on this opportunity by developing innovative treatments, fostering education initiatives, and contributing to a more comprehensive understanding of peanut allergies in both medical communities and the public.

Threat:

Limited access to specialists and treatment centers

Limited access to specialists and treatment centers poses a significant threat to the peanut allergy treatment market. Patients facing peanut allergies may encounter challenges in accessing specialized healthcare professionals and designated treatment facilities. This limitation can hinder timely diagnosis, personalized treatment plans, and the administration of allergen immunotherapy. The scarcity of trained specialists may contribute to gaps in patient care, impacting the effectiveness of interventions.

Covid-19 Impact:

The COVID-19 pandemic has impacted the peanut allergy treatment market by causing disruptions in healthcare services, including allergy diagnostics and treatments. Lockdowns, restrictions, and shifts in healthcare priorities led to delays in patient care, diagnosis, and treatment initiation. Additionally, the pandemic affected clinical trials and research activities, influencing the overall landscape of peanut allergy treatment. As the situation stabilizes, the market is gradually recovering, with an increased emphasis on patient safety and innovative treatment approaches.

The Immunotherapies segment is expected to be the largest during the forecast period

The immunotherapies segment is anticipated to be the largest in the peanut allergy treatment market during the forecast period. This dominance is attributed to the increasing adoption of allergen immunotherapy, including subcutaneous and sublingual approaches, aimed at desensitizing the immune system to peanuts. With a focus on addressing the root cause of peanut allergies and reducing allergic reactions, immunotherapies emerge as a preferred treatment option, contributing to the segment's substantial market share growth.

The injectable segment is expected to have the highest CAGR during the forecast period

The injectable segment is projected to experience lucrative growth in the peanut allergy treatment market during the forecast period. This growth is driven by the increasing preference for injectable forms of treatment, particularly the use of epinephrine auto-injectors for emergency management of severe allergic reactions. With a heightened focus on rapid and efficient intervention during allergic emergencies, the injectable segment is poised for substantial growth, offering a convenient and effective solution for patients and caregivers.

Region with largest share:

North America is poised to dominate the peanut allergy treatment market due to advanced healthcare infrastructure, heightened awareness of peanut allergies, and a proactive regulatory environment. The region's focus on innovative therapies, including immunotherapies, and a higher prevalence of peanut allergies contribute to its market leadership. Additionally, collaborations between healthcare organizations and research institutions further drive advancements in peanut allergy treatment, positioning North America as a key hub for developments and market dominance.

Region with highest CAGR:

The European region foresees rapid growth in the peanut allergy treatment market due to the increasing prevalence of peanut allergies, a strong emphasis on healthcare research, and advancements in treatment options. Rising awareness among healthcare professionals and patients, coupled with supportive regulatory frameworks, propels the adoption of innovative peanut allergy therapies. As research and development efforts intensify, Europe emerges as a significant contributor to advancements in peanut allergy treatment, driving substantial market growth in the forecasted period.

Key players in the market

Some of the key players in Peanut Allergy Treatment Market include Aimmune Therapeutics, ALK-Abello A/S, Alladapt Immunotherapeutics, Inc, AnaptysBio, Inc., DBV Technologies SA, GlaxoSmithKline plc, HAL Allergy Group, Merck & Co., Inc., Mylan N.V., Novartis AG, Pfizer Inc., Prota Therapeutics, Regeneron Pharmaceuticals, Sanofi and Stallergenes Greer.

Key Developments:

In June 2023, Alladapt Immunotherapeutics, Inc. has unveiled topline results of Phase 1/2 Harmony study assessing effectiveness & safety of ADP101 for treating food allergies. Outcomes indicate dose-dependent, clinically significant responses, and a favorable safety profile in pediatric patients with single or multiple food allergies. These promising findings suggest ADP101's potential as a safe and effective treatment for children with common food allergies.

In May 2023, DBV Technologies has made an announcement that the results of its Phase 3 EPITOPE trial involving EPIT using Viaskin Peanut in children aged 1 to 3 years have been published in the New England Journal of Medicine. This publication underscores the potential of a new food allergy treatment option for this specific age group, offering hope for the management of food allergies in young children.

Treatment Types Covered:

  • Epinephrine
  • Antihistamines and Corticosteroids
  • Immunotherapy
  • Other Treatment Types

Route of Administrations Covered:

  • Oral
  • Injectable

End Users Covered:

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Homecare Settings

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Peanut Allergy Treatment Market, By Treatment Type

  • 5.1 Introduction
  • 5.2 Epinephrine
  • 5.3 Antihistamines and Corticosteroids
  • 5.4 Immunotherapy
  • 5.5 Other Treatment Types

6 Global Peanut Allergy Treatment Market, By Route Of Administration

  • 6.1 Introduction
  • 6.2 Oral
  • 6.3 Injectable

7 Global Peanut Allergy Treatment Market, By End User

  • 7.1 Introduction
  • 7.2 Hospitals
  • 7.3 Clinics
  • 7.5 Ambulatory Surgical Centers
  • 7.6 Homecare Settings

8 Global Peanut Allergy Treatment Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Aimmune Therapeutics
  • 10.2 ALK-Abello A/S
  • 10.3 Alladapt Immunotherapeutics, Inc
  • 10.4 AnaptysBio, Inc.
  • 10.5 DBV Technologies SA
  • 10.6 GlaxoSmithKline plc
  • 10.7 HAL Allergy Group
  • 10.8 Merck & Co., Inc.
  • 10.9 Mylan N.V.
  • 10.10 Novartis AG
  • 10.11 Pfizer Inc.
  • 10.12 Prota Therapeutics
  • 10.13 Regeneron Pharmaceuticals
  • 10.14 Sanofi
  • 10.15 Stallergenes Greer